Cempra Gets Easier Path To CRL Response, But Who Will Fund The Study?
Executive Summary
The biotech now only needs to investigate liver toxicity in 6,000 patients – down from 9,000 – to refile its NDA, but Cempra made clear that it won't initiate the study without an external funding source.
You may also be interested in...
Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing
A look at recent developments tracked by the Complete Response Letters chart on the Pink Sheet's US FDA Performance Tracker.
The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin
Cempra Pharmaceuticals appears to be one of the first companies exploring the newly enacted “limited use” pathway for novel antibiotics. The company cited the approach as an option for fusidic acid for use against MRSA – but it sounds like it may also be on the table for the company’s recently rejected solithromycin.
Cempra Goes Back To The Future With New Product/Old Antibiotic Taksta
Cempra's plans to get an old antibiotic product approved at last in the US have received a boost with positive Phase III data, but it still needs to see if the FDA wants another pivotal trial, and analysts are wondering where sales will come from.